The Role of Risk Stratification in Pulmonary Arterial Hypertension

In this video for healthcare professionals, key opinion leaders discuss the role of risk stratification when determining a treatment plan for pulmonary arterial hypertension (PAH) patients as they explore how the 2022 ESC/ERS Treatment Guidelines can be incorporated in U.S. clinical practice.
The focus of this video from the Advancing PAH Care video series is on the progress of what has been learned about risk stratification, the importance of having a more comprehensive picture of patients, via objective, multi-parameter risk assessments and the role of frequent risk assessment to determine treatment regimens.
Speakers:
Dr. Ray Benza, Professor of Medicine at the Icahn School of Medicine at Mount Sinai in New York City, and network director for the Pulmonary Vascular Disease Program at Mount Sinai Heart
Dr. Vallerie McLaughlin, Director of the Pulmonary Hypertension Program and endowed Professor of Medicine at the University of Michigan